Glaxo SmithKline EU Merger Approval Includes Potential Divestment Of Ariflo
Glaxo SmithKline will be required to divest the chronic obstructive pulmonary disease therapy Ariflo in Europe if all competing agents fail in clinical trials.
Glaxo SmithKline will be required to divest the chronic obstructive pulmonary disease therapy Ariflo in Europe if all competing agents fail in clinical trials.